Gene expression profiling identifies FLT3 mutation-like cases in wild-type FLT3 acute myeloid leukemia

Autor: Mosquera Orgueira A, Peleteiro Raíndo A, Cid López M, Antelo Rodríguez B, Díaz Arias JÁ, Ferreiro Ferro R, Alonso Vence N, Bendaña López Á, Abuín Blanco A, Bao Pérez L, Melero Valentín P, González Pérez MS, Cerchione C, Martinelli G, Montesinos Fernández P, Pérez Encinas MM, Bello López JL

Publikováno v: Plos One
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname

FLT3 mutation is present in 25-30% of all acute myeloid leukemias (AML), and it is associated with adverse outcome. FLT3 inhibitors have shown improved survival results in AML both as upfront treatment and in relapsed/refractory disease. Curiously, a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=RECOLECTA___::e0c49a1fa9824bee0ae545250708af27
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=13884

Corrigendum: Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Autor: Mosquera Orgueira A; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Peleteiro Raíndo A; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Díaz Arias JÁ; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Antelo Rodríguez B; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., López Riñón M; Department of Hematology, Tomelloso Hospital, Ciudad Real, Spain., Cerchione C; Unit of Hematology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., de la Fuente Burguera A; Department of Hematology, MD Anderson Cancer Center, Madrid, Spain., González Pérez MS; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Martinelli G; Unit of Hematology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori', Meldola, Italy., Montesinos Fernández P; Department of Hematology, Hospital La Fe, Valencia, Spain., Pérez Encinas MM; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.

Publikováno v: Frontiers in oncology [Front Oncol] 2023 Oct 04; Vol. 13, pp. 1302993. Date of Electronic Publication: 2023 Oct 04 (Print Publication: 2023).

Evaluation of the Stellae-123 prognostic gene expression signature in acute myeloid leukemia.

Autor: Mosquera Orgueira A; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Peleteiro Raíndo A; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Díaz Arias JÁ; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Antelo Rodríguez B; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., López Riñón M; Department of Hematology, Tomelloso Hospital, Ciudad Real, Spain., Cerchione C; Unit of Hematology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'DinoAmadori', Meldola, Italy., de la Fuente Burguera A; Department of Hematology, MD Anderson Cancer Center, Madrid, Spain., González Pérez MS; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain., Martinelli G; Unit of Hematology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) 'DinoAmadori', Meldola, Italy., Montesinos Fernández P; Department of Hematology, Hospital La Fe, Valencia, Spain., Pérez Encinas MM; Department of Hematology, University Hospital of Santiago de Compostela, Santiago de Compostela, Spain.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Aug 17; Vol. 12, pp. 968340. Date of Electronic Publication: 2022 Aug 17 (Print Publication: 2022).

Unsupervised machine learning improves risk stratification in newly diagnosed multiple myeloma: an analysis of the Spanish Myeloma Group.

Autor: Mosquera Orgueira A; Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain., González Pérez MS; Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain., Diaz Arias J; Hospital Clínico Universitario Santiago de Compostela, A Coruña, Spain., Rosiñol L; Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain., Oriol A; Institut Català d'Oncologia I Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain., Teruel AI; Hospital Clínico de Valencia, Valencia, Spain., Martinez Lopez J; Hospital Universitario 12 de Octubre, i+12, Complutense University, CNIO, Madrid, Spain., Palomera L; Hospital Clínico Lozano Blesa, Zaragoza, Spain., Granell M; Hospital Sant Pau, Barcelona, Spain., Blanchard MJ; Hospital Ramón y Cajal, Madrid, Spain., de la Rubia J; Hospital Doctor Peset, Valencia, Spain., López de la Guia A; Hospital Universitario La Paz, Madrid, Spain., Rios R; Hospital Virgen de las Nieves, CIBERESP, Ibs, Granada, Spain., Sureda A; Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de Barcelona, Barcelona, Spain., Hernandez MT; Hospital Universitario de Canarias, Santa Cruz de Tenerife, Spain., Bengoechea E; Hospital de Donostia, San Sebastian, Spain., Calasanz MJ; Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain., Gutierrez N; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, Salamanca, Spain., Martin ML; Hospital Universitario 12 de Octubre, i+12, Complutense University, CNIO, Madrid, Spain., Blade J; Hospital Clínic, Institut d'investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain., Lahuerta JJ; Hospital Universitario 12 de Octubre, i+12, Complutense University, CNIO, Madrid, Spain., San Miguel J; Clínica Universidad de Navarra, CIMA, CIBERONC, IDISNA, Pamplona, Spain., Mateos MV; Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca-Consejo Superior de Investigaciones Científicas), CIBERONC, Salamanca, Spain. mvmateos@usal.es.

Publikováno v: Blood cancer journal [Blood Cancer J] 2022 Apr 25; Vol. 12 (4), pp. 76. Date of Electronic Publication: 2022 Apr 25.

Personally Tailored Survival Prediction of Patients With Follicular Lymphoma Using Machine Learning Transcriptome-Based Models.

Autor: Mosquera Orgueira A; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Cid López M; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Peleteiro Raíndo A; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Abuín Blanco A; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Díaz Arias JÁ; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., González Pérez MS; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Antelo Rodríguez B; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Bao Pérez L; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Ferreiro Ferro R; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain., Aliste Santos C; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain., Pérez Encinas MM; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Fraga Rodríguez MF; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain., Cerchione C; Istituto Tumori della Romagna Istituto Romagnolo per lo Studio dei Tumori (IRST) 'Dino Amadori' - Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS), Meldola, Italy., Mozas P; Hospital Clinic de Barcelona, Barcelona, Spain., Bello López JL; University Hospital of Santiago de Compostela, SERGAS, Santiago de Compostela, Spain.; Health Research Institute of Santiago de Compostela, Santiago de Compostela, Spain.; University of Santiago de Compostela, Santiago de Compostela, Spain.

Publikováno v: Frontiers in oncology [Front Oncol] 2022 Jan 10; Vol. 11, pp. 705010. Date of Electronic Publication: 2022 Jan 10 (Print Publication: 2021).